<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01331486</url>
  </required_header>
  <id_info>
    <org_study_id>09-2279</org_study_id>
    <nct_id>NCT01331486</nct_id>
  </id_info>
  <brief_title>Nitric Oxide Mediated Vasodilatory Response to Hawthorn Standardized Extract</brief_title>
  <official_title>Nitric Oxide Mediated Vasodilatory Response to Hawthorn Standardized Extract</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of North Carolina, Chapel Hill</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prehypertension and mild hypertension affect an estimated 157 million U.S. adults.
      Cardiovascular disease (CVD) risk and associated mortality is elevated in this population.
      Treatment options are limited consisting of lifestyle modification, which is often
      ineffective, or drug therapy, which carries risk of side effects. Highly safe, efficacious,
      and acceptable treatment options for this population are needed. Hawthorn standardized
      extract (HSE) is approved for use in Europe to treat heart failure, and preliminary evidence
      suggests it may have a blood pressure lowering effect. However, prior trials of hawthorn have
      based dosage recommendations on animal studies. Therefore, the investigators propose a
      dose-finding study to measure the pharmacodynamic effect of three doses of standardized
      hawthorn extract and placebo.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>FMD Max</measure>
    <time_frame>7d</time_frame>
    <description>Brachial artery flow mediated dilation max (%)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>BP</measure>
    <time_frame>7d</time_frame>
    <description>Blood pressure</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Prehypertension</condition>
  <condition>Mild Hypertension</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Mid dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Hawthorn</intervention_name>
    <description>Hawthorn standardized extract liquid capsule</description>
    <arm_group_label>Low dose</arm_group_label>
    <arm_group_label>Mid dose</arm_group_label>
    <arm_group_label>High dose</arm_group_label>
    <other_name>Gaia Hawthorn Supreme</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo capsule</intervention_name>
    <description>Matched placebo liquid capsule</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Recent ambulatory daytime systolic BP average between 120 - 155 mmHg or diastolic BP
             between 80-95 mmHg

          2. Age 18 years and older.

          3. Ability to speak English

        Exclusion Criteria:

          1. Any antihypertensive medication use (ACE inhibitors, ARB, beta-blockers, calcium
             channel blockers, diuretics, alpha agonists or antagonists, nitrates, direct
             vasodilators such as hydralazine, aldosterone antagonists, direct renin inhibitors,
             endothelin antagonists)

          2. Current tobacco use.

          3. Diagnosed with diabetes, known coronary artery disease, severe aortic stenosis,
             idiopathic hypertrophic subaortic stenosis (IHSS), or upper extremity vascular
             obstruction.

          4. Pregnancy or breast feeding.

          5. Using estrogen-containing birth control methods.

          6. Unwillingness to forgo vitamins C and E, fish oil, niacin, arginine, OTC
             decongestants, and NSAIDs such as advil, motrin, and nuprin during the study period.

          7. Unwillingness to forgo use of phosphodiesterase inhibitors (sildenafil - 36 hours,
             vardenafil - 36 hours, tadalafil - 96 hours) prior to study visits.

          8. Unwillingness to refrain from vigorous exercise on the morning of study visits.

          9. Women with childbearing potential who do not agree to practice effective birth control
             (condom, diaphragm, cervical cap, copper IUD, abstinence).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gary N Asher, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>UNC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UNC Department of Family Medicine</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Asher GN, Viera AJ, Weaver MA, Dominik R, Caughey M, Hinderliter AL. Effect of hawthorn standardized extract on flow mediated dilation in prehypertensive and mildly hypertensive adults: a randomized, controlled cross-over trial. BMC Complement Altern Med. 2012 Mar 29;12:26. doi: 10.1186/1472-6882-12-26.</citation>
    <PMID>22458601</PMID>
  </results_reference>
  <verification_date>December 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 6, 2011</study_first_submitted>
  <study_first_submitted_qc>April 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2011</study_first_posted>
  <last_update_submitted>February 6, 2013</last_update_submitted>
  <last_update_submitted_qc>February 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 7, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prehypertension</keyword>
  <keyword>Mild hypertension</keyword>
  <keyword>Flow mediated dilation</keyword>
  <keyword>Hawthorn</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Prehypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitric Oxide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

